関連する実験動画
Updated: Jul 19, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
口服レニン阻害剤は,口服レニン阻害剤として使用されています
Jan A Staessen1, Yan Li, Tom Richart
1Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium. jan.staessen@med.kuleuven.be
Lancet (London, England)
|October 24, 2006
まとめ
レニン阻害剤は,心血管および腎臓疾患の治療のためにレニン-アニオテンシンシステムを阻害します. 新しい経口レニン阻害剤であるアリスキレンは,高血圧および関連疾患に対する有望な効果を示しています.
科学分野:
- 薬理学 薬理学とは
- 心血管医学 心血管医学
- ネフロロジーはネフロロジーを用います.
背景:
- レニン-アニオテンシン系は,心血管疾患と腎臓疾患において重要な役割を果たします.
- このシステムの起源であるレニンを阻害することは,30年以上にわたって治療目標となっています.
- 以前の経口レニン阻害剤は,生物学的利用可能性と活性が低いため,臨床的有効性が欠けていました.
研究 の 目的:
- 経口レニン阻害剤の開発をレビューする.
- これらの薬剤の薬理動力学および薬理動力学的特性を要約します.
- 第3相試験における最初の非ペプチドレニン阻害剤であるアリスキレンに焦点を当てること.
主な方法:
- 口服レニン阻害剤に関する臨床前および臨床データのレビュー.
- 薬理動力学および薬理動力学プロファイルの分析.
- 臨床試験におけるアリスキレンの進行に注目する.
主要な成果:
- アリスキレンは,第3相臨床試験に到達した最初の経口活性非ペプチドレニン阻害剤です.
- これは高血圧および関連する心血管および腎臓疾患の治療に潜在性を示しています.
- 強化された特性を有する新しい化合物は,臨床前試験の段階にある.
結論:
- 経口レニン阻害剤は,レニン-アニオテンシン系媒介疾患の管理における重要な進歩を表しています.
- アリスキレンは高血圧および関連疾患の臨床使用の主要候補である.
- 現在進行中の研究は,より優れた生物利用性と有効性を持つ改善された経口レニン阻害剤を開発することを目指しています.
関連する概念動画
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...